Targeting low high-density lipoprotein cholesterol for therapy: lessons from the Veterans Affairs High-density...

Area of Science:

• Cardiology
• Endocrinology
• Pharmacology

Background:

• Low high-density lipoprotein cholesterol (HDL-C) is a risk factor for coronary artery disease (CAD).
• The Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT) investigated interventions for men with established CAD and low HDL-C.

Purpose of the Study:

• To evaluate the efficacy of gemfibrozil, a fibric acid derivative, in reducing CAD events.
• To assess the relationship between achieved HDL-C levels and CAD event reduction.
• To determine the benefit of gemfibrozil in patients with metabolic syndrome features.

Main Methods:

• A randomized, placebo-controlled trial (VA-HIT) involving men with known CAD and low HDL-C.
• Treatment with gemfibrozil versus placebo.
• Monitoring of CAD events and lipid profiles, including HDL-C levels.

Main Results:

• Gemfibrozil significantly decreased the incidence of CAD events compared to placebo.
• CAD event reduction was inversely correlated with HDL-C levels achieved during treatment.
• Patients with low HDL-C and features of metabolic syndrome (obesity, type 2 diabetes, hyperinsulinemia) showed a pronounced benefit from gemfibrozil.

Conclusions:

• Gemfibrozil therapy is effective in reducing CAD risk in men with low HDL-C.
• Fibrate therapy may be a valuable strategy for managing CAD risk, especially in populations with increasing rates of obesity and diabetes.
• The findings highlight the importance of addressing low HDL-C and metabolic syndrome in cardiovascular disease prevention.